

## **BAB 5**

### **KESIMPULAN DAN SARAN**

#### **5.1 Kesimpulan**

Dari hasil penelitian studi penggunaan amiodaron pada pasien atrial fibrilasi di RSUD Kabupaten Sidoarjo pada periode Januari 2019 sampai dengan Desember 2019, dapat disimpulkan bahwa :

1. Penggunaan terapi amiodaron pada pasien atrial fibrilasi sebanyak 148 pasien (88%) dan penggunaan amiodaron kombinasi dengan obat yang memiliki efek inotropik lain sebanyak 9 pasien (12%)
2. Regimen terapi amiodaron tunggal pada pasien atrial fibrilasi paling banyak amiodaron (600mg/18 jam) i.v sebanyak 57 pasien (39%) dan regimen terapi amiodaron kombinasi dengan obat inotropik pada pasien atrial fibrilasi paling banyak amiodaron (3x200mg) p.o dengan digoksin (1x0,25mg) p.o. sebanyak 4 pasien (45%) (Satu pasien dapat memiliki lebih dari satu kombinasi terapi).
3. Pola pergantian penggunaan amiodaron tunggal paling banyak adalah regimen amiodaron (300mg/6 jam) i.v. → (600 mg/18 jam) i.v. → (3x200mg) p.o dengan prevalensi 10 pasien (21%) dan 4 pasien (8%) mengalami perubahan pergantian dari amiodaron tunggal menjadi kombinasi dengan digoksin.

## **5.2 Saran**

- 1 Penggunaan amiodaron pada pasien atrial fibrilasi di RSUD Kabupaten Sidoarjo memerlukan peran serta dari tenaga kefarmasian dalam meningkatkan optimalisasi terapi dan dalam rangka meningkatkan kualitas hidup pasien dan menurunkan angka morbiditas dan mortalitas.
- 2 Untuk mendapatkan hasil yang optimal diperlukan penelitian yang bersifat prospektif agar peneliti dapat melihat secara langsung perkembangan kondisi pasien.
- 3 Penelitian selanjutnya dapat menggunakan periode penelitian yang lebih lama dan sampel yang lebih banyak agar mendapatkan hasil yang lebih representatif.
- 4 Diperlukan penulisan RMK yang lebih lengkap, sehingga didapatkan data yang lebih baik untuk penelitian selanjutnya.

## DAFTAR PUSTAKA

- ACC/AHA, 2014. Guidelines for the Management Patients With Atrial Fibrillation. *Journal of the American College of Cardiology*.
- American Society of Health-System Pharmacists, 2011. *AHFS Drug Information Essentials*. American Society of Health-System Pharmacists. Maryland.
- Bart A.M., Dirk J.V.V., Harry J.G.M., Jan G P Tijssen, Hans Hillege, Marco Alings, Michiel Rienstra, Maarten P Van den Berg, Isabelle C Van Gelder, 2014. Digoxin in Patients with Permanent Atrial Fibrillation: Data from the RACE II study. *Heart Rhythm: The Official Journal of the Heart Rhythm Society*, **11(9)**.
- Bauer, L.A. 2012. Digoxin. In: *Applied Clinical Pharmacokinetics*. United States of America: The McGraw-Hill Companies, pp 265- 273.
- Boitano Scott., Brooks H.,L, 2010. *Ganong 's Review of Medical Physiology*, 23<sup>rd</sup> Edition, The McGraw Hill Companies. New York.
- Charles R. Craig dan Robert E.stitzel., 2004. *Modern Pharmacology With Clinical Applications*, 6<sup>th</sup> Edition, Lippincot Williams and Wilkins. Philadelphia.
- Chern-En Chiang, Tsu-Juey Wu, Kwo-Chang Ueng., 2016. Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation, *Journal of the Formosan Medical Association*, **115**:893-952.
- Connolly, S. J., 2006. Comparison of  $\beta$ -Blockers, Amiodarone Plus  $\beta$ -Blockers, or Sotalol for Prevention of Shocks From Implantable Cardioverter DefibrillatorsThe OPTIC Study: A Randomized Trial. *Journal American Medical Association*, **295(2)**.
- Coon J.C., 2011. Pharmacotherapy for Acute Heart Failure Syndromes, *American Journal of Health-system Pharmacy*, **68(1)**:21-35.
- D'Alessandro, A., Boeckelmann, I., Hammwhoner, M., dan Goette, A. 2012. Nicotine, cigarette smoking and cardiac arrhythmia: an overview. *European Journal of Preventive Cardiology*, **19**:297.
- Daisuke Horiuchi, MD, Shingo Sasaki, MD, Takahiko Kinjo, MD, Yuji Ishida, MD, Taihei Itoh, MD, Kenichi Sasaki, MD, Shingen Owada, MD, Masaomi Kimura, MD, Ken Okumura, MD., 2014. Rhythm and

- Rate Control Effects of Intravenous Amiodarone for Atrial Fibrillation Complicated by Acutely Decompensated Heart Failure, *Journal of Arrhythmia*, **30(3)**: 167-172.
- DiPiro J.T., Wells B.G., Schwinghammer T.L. and DiPiro C. V., 2015, *Pharmacotherapy Handbook*, 9<sup>th</sup> Edition, McGraw-Hill Education Companies, Ingris.
- European Society of Cardiology, 2016. Guidelines for the Management of Atrial Fibrillation., *European Heart Journal*.
- Gama, H., 2008. *Drug Utilization Studies*, Arquivos De Medica, **22(23)**: 69.
- Goodman and Gilman's., 2008. *Manual Pharmacology and Therapeutics.*, McGraw-Hill Education Companies, USA.
- Guyton A.C. dan Hall E.J., 2006, *Textbook of Medical Physiology*, 11<sup>th</sup> Edition. Elseivers Saunders. Philadelphia.
- Hooft, C.S., Heeringa,, J., Herpen, G. V., Kors, J. A., Kingma, J. H., Stricker, B. H. C. 2004. Drug Induced Atrial Fibrillation. *Journal of American College of Cardiology*, **44(11)**: 2117-2124.
- Jonathan M.K., Peter M.K., *et al*, 2016. Comorbidity of Atrial Fibrillation and Heart Failure. *Nature Reviews Cardiology*, **13(3)**: 131-147.
- Karamichalakis, N., Letsas, K. P., Georgopoulos, S., Bakalakos, A., Efremidis, M., Sideris A., 2015. Managing atrial fibrillation in the very elderly patient: challenges and solutions. *Vascular Health and Risk Management*, **11**: 555–562.
- Katzung, B. G. and Trevor, A. J. 2015. *Basic & Clinical Pharmacology*, 13<sup>th</sup> Edition, McGraw Hill Education Lange. New York.
- Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H., Heidbuchel, H., Hendriks, J., Hindricks, G., Manolis, A. S., Oldgren, J., Popescu, B. A., Schotten, U., Putte, B. V., Vardas, P. 2016. ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS. *European Heart Journal*, **37**: 2893-2962.
- Klabunde, R. E. 2012. Cardiac Glycosides (Digitalis Compounds), *Cardiovascular Pharmacology Concepts*, diakses pada 27 Januari 2020,  
<http://www.cvpharmacology.com/cardiostimulatory/digitalis.html>.

- Lacy, C.F., Armstrong, L.L., Goldman, M.P., Lance, L.L. 2009. *Drug Information Handbook*. Hudson, Ohio: Lexi-Comp, Incorporation. American Pharmaceutical Association.
- Lippi, G., Sanchis-Gomar, F., & Cervellin, G., 2020. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. *International Journal of Stroke*, **0(0)**: 1–5
- Long B., Koefman A., Gottlieb M., 2018. Management of Heart Failure in the Emergency Department Setting: An Evidence-Based Review of the Literature. *The Journal of Emergency Medicine*. **55(5)**: 635-646.
- McPhee, Stephen J. Hammer, Gary D. 2005. *Pathophysiology of Disease: An Introduction to Clinical Medicine*, 4<sup>th</sup> Edition, pp. 219-220.
- Muchtar, A. dan Suyatna, F.D. 2009. Obat Antiaritmia. Dalam: *Farmakologi dan Terapi* edisi V. Jakarta: Balai Penerbit FKUI.
- Moore, K.L., Arthur, F., Dalley, 2010, *Clinically Oriented Anatomy*, Lippincott Williams dan Wilkins, Philadelphia.
- NICE., 2014, *Atrial Fibrillation National Clinical Guideline for Management in Primary and Second Care*. Royal College of Physicians, London.
- Oemar, H., 2004, *Buku Ajar Kardiologi*, Fakultas Kedokteran Universitas Indonesia, Jakarta, pp 7-10.
- Olgin J.E., Zipes D.P., 2007, *Specific Arrhythmias Diagnosis and Treatment*, 8<sup>th</sup> Edition, Elseivers Saunders. Philadelphia.
- Perhimpunan Dokter Spesialis Kardiovaskular Indonesia, 2014. *Pedoman Tata Laksana Fibrilasi Atrium*. Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI).
- Rode D.M., 2008, Obat-Obat Antiaritmia. *Goodman & Gilman Dasar Farmakologi Terapi* edisi X. Jakarta: Penerbit Kedokteran EGC.
- Ronny., Setiawan., Fatimah Sari, 2008. *Fisiologi Kardiovaskular: Berbasis Masalah Keperawatan*. Kedokteran EGC. Jakarta.
- Safrina, U., 2014, Studi Penggunaan Antikoagulan pada Pasien Atrial Fibrilasi, *Skripsi*, Sarjana Farmasi, Universitas Airlangga.
- Sachdeva, P.D., 2010, Drug Utilization Studies-Scope and Future Perspectives, *International Journal on Pharmaceutical and Biological Research*, **1(1)**: 11-15.

- Scheinman M.M., 2002, *Current Diagnosis and Treatment in Cardiology*, 2<sup>nd</sup> Edition, McGraw Hill.
- Schmidt, Constanze., 2011, The Pathology and Treatment of Cardiac Arrhythmias: Factor on Atrial Fibrillation, *Valvular Health and Risk Management*, **7**: 193–202.
- Siddoway, L. A., MD., 2003, Amiodarone: Guideline for Use and Monitoring. *American Family Physician*, **68(11)**: 2189-2197.
- Stockley, I. H dan Baxter, K. Eds. 2010. *Stockley's Drug Interaction Pocket Companion 2010*. United States of America: Pharmaceutical Press.
- Sukandar, Prof. Dr. Elin Yulinah, Apt., 2008, *ISO Farmakoterapi*. Jakarta, PT. ISFI Penerbitan.
- Tisdale, J. E., 2016. Arrhythmias. In: Chisholm-Burns, M. A., Schwinghammer, T. L., Wells, B. G., Malone, P. M., Kolesar, J. M., DiPiro, J. T., (Eds). *Pharmacotherapy Principles & Practice*, 4<sup>th</sup> Edition, New York: McGraw Hill Education.
- Tortora, G.J., Derrickson, B., 2009, *Principles of Anatomy and Physiology*, 12<sup>th</sup> Edition, John Wiley & Sons, Hoboken.
- Wilhelm, M. 2013. Atrial Fibrillation in Endurance Athletes. *European Journal of Preventive Cardiology*, **21(8)**: 1040–1048.
- White, C. M., Song, J. C., dan Kalus, J. S. 2009. Chapter 19: Cardiac Arrhythmia. *Applied Therapeutics: The Clinical Use of Drugs*. United States of America: Lippincott Williams & Wilkins.
- Yuniadi, Y, 2009. Clinical Application of Amiodarone Trials. *Jurnal Kardiologi Indonesia*, **30**: 25-31.